87 Recruiting Pancreatic Ductal Adenocarcinoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Pancreatic Ductal Adenocarcinoma
Related Conditions
Top Recruiting Pancreatic Ductal Adenocarcinoma Studies
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
📍 University of Rochester — Rochester, New York
View Study & Checklist ➔Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
📍 University of Kansas Cancer Center — Kansas City, Kansas
View Study & Checklist ➔Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
📍 Duke University Health System — Durham, North Carolina
View Study & Checklist ➔Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
📍 Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
View Study & Checklist ➔A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
📍 Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania
View Study & Checklist ➔A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma
📍 University of Southern California — Los Angeles, California
View Study & Checklist ➔A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
📍 Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
View Study & Checklist ➔Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma
📍 CHUM — Montreal, Quebec
View Study & Checklist ➔A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
View Study & Checklist ➔PHL Treatment in Pancreatic Cancer
📍 Fox Chase Cancer Center — Philadelphia, Pennsylvania
View Study & Checklist ➔Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
📍 USC Norris Comprehensive — Los Angeles, California
View Study & Checklist ➔A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔High Resolution Ultrasound in Pancreatic Ductal Adenocarcinoma
📍 University Health Network — Toronto, Ontario
View Study & Checklist ➔The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
📍 University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center — Cleveland, Ohio
View Study & Checklist ➔A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
📍 Baylor College of Medicine — Houston, Texas
View Study & Checklist ➔Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
📍 Uni of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Durvalumab and Oleclumab in Resectable PDAC
📍 Princess Margaret Cancer Centre — Toronto, Ontario
View Study & Checklist ➔Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
📍 Roswell Park Comprehensive Cancer Center — Buffalo, New York
View Study & Checklist ➔A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
📍 Cedars-Sinai Medical Center — Los Angeles, California
View Study & Checklist ➔Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
📍 The University of Texas Health Science Center at Houston — Houston, Texas
View Study & Checklist ➔Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
📍 Cooperman Barnabas Medical Center (Saint Barnabas Medical Center) — Livingston, New Jersey
View Study & Checklist ➔A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
📍 Karmanos Cancer Center — Detroit, Michigan
View Study & Checklist ➔MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
📍 City of Hope — Duarte, California
View Study & Checklist ➔A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
📍 Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
View Study & Checklist ➔A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
📍 BC Cancer — Vancouver, British Columbia
View Study & Checklist ➔A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
📍 Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
View Study & Checklist ➔Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
📍 Novartis Investigative Site — Montreal, Quebec
View Study & Checklist ➔Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
📍 Northwell Health R.J. Zuckerberg Cancer Center — Lake Success, New York
View Study & Checklist ➔PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
📍 Hoag Memorial Hospital Presbyterian — Newport Beach, California
View Study & Checklist ➔Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
📍 Imbert Cancer Center — Bay Shore, New York
View Study & Checklist ➔Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
📍 University of California, San Francisco — San Francisco, California
View Study & Checklist ➔A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Lead-212 PSV359 Therapy for Patients With Solid Tumors
📍 University of Miami — Miami, Florida
View Study & Checklist ➔